Literature DB >> 7693046

Exogenous tat protein activates human endothelial cells.

F M Hofman1, A D Wright, M M Dohadwala, F Wong-Staal, S M Walker.   

Abstract

tat protein, a human immunodeficiency virus (HIV) gene product that functions as a transactivator for HIV replication, is known to be secreted extracellularly by infected cells. To determine the potential role of tat in the dissemination of HIV into extravascular tissue, this protein was examined for its ability to activate human endothelial cells. The results show that tat does indeed stimulate endothelial cells. This is evidenced by their expression of the endothelial-leukocyte adhesion molecules, E-selectin, critical for the initial binding of leukocytes to the blood vessel wall, and their increased synthesis of interleukin-6 (IL-6), a cytokine known to enhance endothelial cell permeability. Furthermore, tat acts synergistically with low concentrations of tumor necrosis factor-alpha to enhance IL-6 secretion. These data suggest that extracellular tat protein secreted or released into the microenvironment may contribute significantly to the determination of specific sites of leukocyte binding to blood vessels, to transmigration into tissue, and to eventual dissemination of HIV-infected cells or free virions into tissue.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693046

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  Regulation of HIV-1 transcription.

Authors:  K A Roebuck; M Saifuddin
Journal:  Gene Expr       Date:  1999

2.  Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells.

Authors:  S Mitola; R Soldi; I Zanon; L Barra; M I Gutierrez; B Berkhout; M Giacca; F Bussolino
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 3.  Expanding role of circulating adhesion molecules in assessing prognosis and treatment response in human immunodeficiency virus infection.

Authors:  Nikolaos V Sipsas; Petros P Sfikakis
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

4.  Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes.

Authors:  R Anderson; S Wang; C Osiowy; A C Issekutz
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

Review 5.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

6.  Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine.

Authors:  Leslie Spikes; Pranjali Dalvi; Ossama Tawfik; Haihua Gu; Norbert F Voelkel; Paul Cheney; Amy O'Brien-Ladner; Navneet K Dhillon
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

7.  Human endothelial cells enhance human immunodeficiency virus type 1 replication in CD4+ T cells in a Nef-dependent manner in vitro and in vivo.

Authors:  Jaehyuk Choi; Jason Walker; Sergei Boichuk; Nancy Kirkiles-Smith; Nicholas Torpey; Jordan S Pober; Louis Alexander
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 8.  Current update on HIV-associated vascular disease and endothelial dysfunction.

Authors:  Hong Mu; Hong Chai; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

9.  Vitreous body affects activation and maturation of monocytes into macrophages.

Authors:  R Osuský; S M Walker; S J Ryan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-10       Impact factor: 3.117

10.  Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension.

Authors:  Priscilla Y Hsue; Steven G Deeks; Husam H Farah; Swapna Palav; Samira Y Ahmed; Amanda Schnell; Allison B Ellman; Laurence Huang; Sheila C Dollard; Jeffrey N Martin
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.